+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effects of the ABC Bicuspid Sizing Algorithm on patients with bicuspid aortic stenosis undergoing transcatheter aortic valve replacement TAVR using the Sapien 3 valve. This international, multi-center study aims to determine if the algorithm improves technical success immediately after the procedure and device success 30 days later. The study also examines how additional imaging techniques like gated computed tomography and artificial intelligence-based simulations influence treatment decisions. The study involves about 290 patients eligible for TAVR or surgical aortic valve replacement SAVR. Physicians use the ABC Bicuspid Sizing Algorithm to guide treatment allocation between TAVR and SAVR, as well as valve sizing and deployment for those receiving TAVR. Some patients may have further evaluation with gated CT or AI simulations to assess risks. Data for TAVR patients is collected at baseline, during the procedure, at hospital discharge, 30 days after, and annually up to 5 years. SAVR patients have data collected at baseline and during the procedure only. Participants will undergo diagnostic imaging including CT scans evaluated with the sizing algorithm and may receive additional assessments if indicated. Researchers collect data on procedure success, device outcomes, conduction disturbances, pacemaker implants, stroke, vascular complications, mortality, valve function, and hospitalizations for heart failure over 5 years. Follow-up visits occur at 30 days and annually, allowing long-term monitoring of outcomes after treatment.

All AgesAll Genders
20 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the Edwards SAPIEN X4 and X4S Transcatheter Heart Valves in people with severe, symptomatic calcific aortic stenosis. This is a prospective, single-arm, multicenter study that includes a separate registry for subjects with bicuspid aortic valve morphology. The study aims to provide important data on these balloon-expandable bioprosthetic valves in this patient population. Participants will undergo a transcatheter aortic valve replacement TAVR procedure using either the SAPIEN X4 or SAPIEN X4S valve. Those with bicuspid aortic valves will be enrolled in a separate registry and also undergo TAVR. The study involves implantation of the valve device via catheter, with no randomization or comparison groups. The primary study period extends up to one year after the procedure. During the study, participants will be monitored through regular assessments including evaluation of survival and stroke occurrence at one year. Secondary outcomes include quality of life measured by the Kansas City Cardiomyopathy Questionnaire, paravalvular leak assessment at 30 days, and new permanent pacemaker implantation also at 30 days. Edwards Lifesciences sponsors the study, and participants will be followed until study completion in 2037 to monitor safety and effectiveness outcomes.

All AgesAll GendersPhase Not Applicable
65 locations
C

Actively Recruiting

Researchers are studying endometrial cancer, the most common gynecological cancer, focusing on the value of sentinel node biopsy SNB compared to no retroperitoneal node dissection. The study aims to assess if SNB affects patient recovery, morbidity, quality of life, healthcare costs, and disease-free survival. This Phase III randomized clinical trial addresses ongoing controversy over lymph node dissections benefits and risks in early-stage endometrial cancer treatment. Participants are randomly assigned to one of two groups one receiving total laparoscopic or robotic hysterectomy with bilateral salpingo-oophorectomy TH BSO combined with SNB using dye injections to identify sentinel lymph nodes, and the other receiving TH BSO without retroperitoneal node dissection. Some may omit ovary removal if under 45 with specific cancer features. The trial includes two stages the first with 444 patients focusing on recovery and quality of life, and the second with 316 patients evaluating disease-free survival over 4.5 years. During the study, participants undergo surgery followed by multiple assessments including quality of life questionnaires, clinical evaluations for lymphoedema and adverse events, imaging, and molecular profiling. Researchers measure recovery at 12 months and disease-free survival at 4.5 years, along with cost-effectiveness, treatment requirements, and recurrence patterns. The total participation duration extends up to 4.5 years to monitor long-term outcomes and safety.

Age: 18Years +FEMALEPhase 3
23 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the F2 Cerebral Protection Catheter CPC compared to a control group without embolic protection in adults undergoing transfemoral Transcatheter Aortic Valve Replacement TF TAVR. The study aims to show that the F2 CPC is as safe as no protection and performs better in preventing embolic events during the procedure. This is a prospective, randomized, single-blind trial involving multiple centers. Participants will be assigned randomly to one of two groups one group will receive the F2 Cerebral Embolic Protection System during their TF TAVR procedure, while the control group will undergo the procedure without any embolic protection device. The study uses commercially available TAVR devices and compares outcomes between these two approaches. This treatment phase focuses on the procedure itself and the use or non-use of the F2 CPC device. During and after the procedure, participants will be closely monitored for neurological protection effectiveness and major adverse events up to 30 days post-procedure. Assessments include brain imaging with diffusion-weighted MRI within 8 to 72 hours after the procedure and evaluations of safety and vascular complications by discharge or day 5 to 10, with follow-up on day 30. Participants will undergo various tests and evaluations to measure brain lesions, kidney function, bleeding, and vascular complications, ensuring thorough monitoring throughout the study period.

Age: 21Years - 90YearsAll GendersPhase Not Applicable
10 locations